Trelagliptin (syr-472, zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (dpp-4) via a non-covalent mechanism
Authorization for pediatric patients aged 12 years and older followed in 2022
CrossRef Repurposing HIV-Protease Inhibitor Precursors as Anticancer Agents: The Synthetic Molecule RDD-142 Delays Cell Cycle Progression and Induces Autophagy in HepG2 Cells with Enhanced Efficacy via Liposomal Formulation Fabiana Crispo, Antonio Vassallo, Immacolata Faraone, Alessandro Santarsiere, Lucia Chiummiento, Mara Martinelli, Nicoletta Cascelli, Xavier Fernndez-Busquets, Rocchina Miglionico, Ilaria Nigro, Carla Caddeo, Maria Francesca Armentano International Journal of Molecular Sciences .2025
10 mgLyophilized powder, single vialProcurement inquiry only $99.00Listed price planning Supplier-listed target specification: 99% (HPLC) Not a lot-specific test result
Fights inflammation and helps support the immune system
But, because it is a consumable, consumers can stop when they lose enough weight